Phase I accelerated dose-escalation study to determine the safety and tolerability of CYT997 when given as an oral capsule every two weeks in patients with advanced solid tumours.

Trial Profile

Phase I accelerated dose-escalation study to determine the safety and tolerability of CYT997 when given as an oral capsule every two weeks in patients with advanced solid tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Lexibulin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors YM BioSciences Australia
  • Most Recent Events

    • 25 Feb 2009 Status changed from recruiting to completed, as reported in the Australian New Zealand Clinical Trials Registry.
    • 26 May 2008 The expected completion date for this trial is now 1 Oct 2008.
    • 19 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top